# AIM catalysts: AIM ImmunoTech Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aim/catalysts

> AIM ImmunoTech Inc. (AIM) has 1 upcoming catalyst. The next is the RASONQUE (daraxonrasib) topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for AIM?

AIM ImmunoTech Inc. (AIM) has 1 upcoming catalyst. The next is the RASONQUE (daraxonrasib) topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "2 DURIPANC topline results expected in Q1 2027, with additional clinical and immune-response analyses anticipated in Q3 2027" [Calendar and source filings](https://sec-api.dev/companies/aim/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-050093, https://www.sec.gov/Archives/edgar/data/946644/000149315226050093/ex99-2.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/aim/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | AIM ImmunoTech Inc. |
| Ticker | AIM (NYSE) |
| SEC CIK | 946644 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/aim |

## Cash runway

Cash $6.9M as of 2026-09-30; quarterly burn $2.9M; about 7.1 months of runway at that rate (XBRL company facts, accession 0001493152-26-051439).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | AIM |  | completed | "In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist)" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm)) |
| Sep 2022 | [Ampligen® (rintatolimod) topline data readout](https://sec-api.dev/pdufa/rintatolimod) | AIM |  | completed, negative | "The now completed (as of September 2022) topline results from the study confirm the positive findings that were previously presented at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in a poster presentation titled Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm)) |
| Jul 2023 | [AMP-518 trial start](https://sec-api.dev/pdufa/amp-518) | AIM | post-COVID conditions | completed | "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm)) |
| September 30, 2024 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended September 30, 2024 and 2023, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315224045971/form10-q.htm)) |
| December 31, 2024 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the years ended December 31, 2024 and 2023, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm)) |
| March 31, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended March 31, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000164117225011033/form10-q.htm)) |
| June 30, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended June 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm)) |
| September 30, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended September 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm)) |
| August 7, 2026 | [Ampligen® (rintatolimod) earnings report](https://sec-api.dev/pdufa/rintatolimod) | AIM |  | completed | "ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/ex99-1.htm)) |
| Q1 2027 | [RASONQUE (daraxonrasib) topline data readout](https://sec-api.dev/pdufa/daraxonrasib) | AIM |  | scheduled | "2 DURIPANC topline results expected in Q1 2027, with additional clinical and immune-response analyses anticipated in Q3 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/946644/000149315226050093/ex99-2.htm)) |

## Drugs

- [AMP-518](https://sec-api.dev/pdufa/amp-518): post-covid conditions
- [Protocol](https://sec-api.dev/pdufa/protocol): 
- [Ampligen® (rintatolimod)](https://sec-api.dev/pdufa/rintatolimod): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aim/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AIM catalysts: AIM ImmunoTech Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aim/catalysts

```bibtex
@misc{secapidev_companies_aim_catalysts_20261116,
  title        = {AIM catalysts: AIM ImmunoTech Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aim/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aim_catalysts_20261116","title":"AIM catalysts: AIM ImmunoTech Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aim/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
